| |
CEF20  |
|
|
| Cat. No. |
Size |
Price |
Figures |
|---|
RP11781-1 mg
| 1 mg | $ 71.25 | HPLC: 20050919140131 (PDF)
MS: 20050919140153 (PDF)
MSDS: 20071223213606 (PDF)
STRUCTURE:
Zoom
References:
- Wills MR, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. Nov 1996; 70(11): 7569-7579.
- Zaia JA, et al. Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates. J. Virol. Mar 2001; 75(5): 2472-2474.
- La Rosa C, et al. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood. Mar 2001; 97(6): 1776-1786.
|
|---|
| Full Name | |
| Alias |
CEF20, Cytomegalovirus, CMV pp65 (495-503) |
Sequence
(one-letter code) |
NLVPMVATV | Sequence
(three-letter code) | {ASN}{LEU}{VAL}{PRO}{MET}{VAL}{ALA}{THR}{VAL} |
|---|
| Description | CEF20, a CEF control peptide pool, is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503). Such epitopes are useful in applications such as ELISPOT, intracellular cytokine, and CTL assays, and they also provide as net weight based on peptide content. |
|---|
| Solubility | Soluble in water |
|---|
| Formula | C42H74N10O12S1 |
|---|
| M.W. | 943.18 |
|---|
| Purity | 95% |
|---|
| Storage | Store at -20°C |
|
